BACKGROUND: Pituitary adenomas are rare with an incidence of 0.4-8.2 per 10 5 inhabitants. Symptoms range from headaches to pituitary insufficiency or excessive output of hormones with associated disease. Except for prolactinomas, surgery is recommended as the first line and most effective treatment for the majority of these tumours. One of the refinements of surgical therapy introduced was intraoperative magnetic resonance imaging (iMRI). OBJECTIVE: The aim of this study was to analyse the postoperative pituitary function and the general outcome of patients treated for non-functioning and GH-producing pituitary adenomas with a transsphenoidal iMRI-assisted approach using the PoleStar™ N20 imager. METHODS: A total of 148 consecutive iMRI-guided surgeries for GH-producing and non-functioning pituitary adenomas were retrospectively analysed. Patients' clinical data, endocrinological parameters, clinical examinations and pre-/post-and intraoperative imaging studies were evaluated. RESULTS: A total of 101 patients could be classified as being in remission at follow-up; 26 (17.6%) of them due to iMRI allowing additional tumour removal. A total of 44 patients (29.7%) had more complete tumour removal because remnants were detected by iMRI.
Introduction
Pituitary adenomas (PA) are rare neoplasm with an estimated incidence of 0.4-8.2 per 10 5 inhabitants [1] [2] [3] . Symptoms range from headache and cranial nerve palsy -being signs of elevated intracranial pressure or direct compression of neural structures [4, 5] , to endocrinological deficiency or excessive output of hormones with associated disease [6, 7] . Diagnosis is usually established by computed tomography (CT) or magnetic resonance imaging (MRI) performed for investigation of neurological symptoms or endocrinological disturbances and endocrinological examination including hormone blood levels. Acromegaly is a rare disease with an estimated incidence of about 4 per 10 6 inhabitants. In most cases, it is caused by a growth-hormone (GH)-producing pituitary adenoma (PA). If excessive output of GH is not normalised, severe cardiovascular and metabolic disturbances as well as cosmetic and orthopedic deformities will result. Previously published studies have shown a 2-3-fold increased mortality for treatment-resistant cases as compared to successfully treated patients and healthy individuals [8] [9] [10] . Correction of GH values to normal can restore life expectancy towards normal. First surgical treatment using a trans nasal approach in an acromegalic patient was performed by Dr. Schloffer in Vienna in 1907 [11] . Non-functioning pituitary adenomas (NFPAs) add up to 25-30% of all PAs with an estimated incidence of 0.1-3.0 per 10 5 inhabitants [7, 12, 13] . The symptoms of NFPAs are caused by the tumour's mass effect, which results in headache due to stretching of the diaphragma sellae and the sellar dura and visual deficits due to chiasmal compression. Diplopia may occur as a result of lateral tumour growth and/or haemorrhage into the cavernous sinus. In addition, patients can develop symptoms of secondary pituitary insufficiency due to compression of the pituitary gland [6, 7] . Visual disturbances occur in 53.8-74% [4, 5] headaches in 9.7-56% [4, 14] , and third nerve palsy in 12% [4] . Except for asymptomatic micro-PAs and for prolactinomas, surgery is generally recommended as treatment of choice [1, 6, [15] [16] [17] [18] [19] [20] [21] . As most pituitary adenomas are benign neoplasms, tumour control can be achieved by complete resection. Today, most patients receive surgery as first line treatment using a transnasal, transsphenoidal approach introduced by Cushing [22] and reintroduced using microsurgical techniques by Hardy in 1979 [23] . In cases successfully treated by surgery, the outcome is defined by persisting neurological symptoms and pituitary function. A requirement for hormone replacement therapy is associated with the inconvenience of daily medication and regular tests whether the treatment is appropriate; moreover, hormone substitution is also an important socioeconomic factor as replacement therapy can generate costs being a multiple of the initial surgical treatment. In recent years there have been a lot of refinements in the surgical treatment of PA like improvement of endoscopy and introduction of intraoperative magnetic resonance imaging (iMRI) [21, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Those treatment options have been analysed regarding the clinical outcome and tumour control and showed superior results in the treatment of certain PAs (i.e., Growth hormone producing PA) compared to the conventional surgical approach. Endocrinological outcome has only been a minor part in those studies as the research focus concentrated mainly on tumour control. In this largest study to date we analysed the postoperative pituitary function and the general outcome of 148 consecutive surgical procedures for non-functioning and GH-producing PAs being treated using a transnasal, transsphenoidal microsurgical iMRI-assisted approach using the PoleStar N20 imager.
Patients and methods

Patient demographics (table 1)
A total of 148 surgical procedures were performed in 145 patients (82 male, 63 female) suffering from non-functioning-or GH-producing PA between September 2005 and August 2009. The data of those patients was prospectively collected and retrospectively analysed. Inclusion criteria of this study were diagnosis of a GH-producing-or NFPA and iMRI-assisted tumour removal. There were no exclusion criteria. A total of 39 patients presented with GH-producing PA and 109 patients with NFPA. Three patients (1 male, 2 female) underwent surgery twice for removal of recurrent tumour. All patients were operated on by the senior author (R.L.B.) using the same standardised transsphenoidal approach with the aid of ultra low-field iMR imaging. The mean patient age was 55 ± 15 years (range 19-80 years). The median preoperative tumour volume was 6797 mm 3 (range 50-65, 450 mm 3 ; mean diameters 23mm*20mm*19mm). Ten cases (6.9%) presented with microadenomas, 118 (82.5%) with macroadenomas, and 15 (10.5%) with giant adenomas. A total of 24 patients (17.1%) had previous pituitary surgery. In 51 cases (35.7%) the tumour invaded the cavernosus sinus. Overall, 89 patients (62.2%) had cranial nerve symptoms, among them 79 (55.2%) with visual field deficits. 56 patients (37.8%) complained about headache. In 37 out of the 39 cases (94.8%) with GH-producing PA, patients had symptoms of acromegaly. There were no patients with somatostatin receptors ligands therapy in the GH-producing PA group and no patients with previous radiotherapy.
Pre-and postoperative management
Patients were seen as outpatients before surgery. After decision for surgical treatment, patients arrived in hospital the day before surgery. Preoperative diagnostics included computed tomography (CT) scan and magnetic resonance imaging (MRI) for determination of the pituitary adenoma, bony and neurovascular structures. Pre-and postoperative imaging studies were performed at the Department of Neuroradiology, University Hospital of Zurich. CT studies were performed on a 16 slice CT scanner (Siemens SOMATON ® Sensation, München, Germany) acquiring non contrast-enhanced and contrast-enhanced multi slice imaging data. The MRI studies were performed on a 1.5 Tesla MR tomography scanner (Signa ® , General Electric, Milwaukee, USA). Neurological and ophthalmological examinations were performed after admission. General patient data, additional diagnosis, medication at admission and previous study results were noted. Patients underwent endocrinological examination which included blood analysis for pituitary function examining growth hormone (GH), insulin-like growth factor-1 (IGF-1), adrenocorticotropin (ACTH), cortisol, thyroid stimulating hormone (TSH), fT4, fT3, prolactin, luteinising hormone (LH), follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG); testosterone was measured in male and estradiol in female patients unless a history of recent menstrual bleedings or of contraceptive pill intake was given. Patients signed written consent for the surgical procedure and general anaesthesia. On the day of surgery, patients with reduced Cortisol plasma levels received 100 mg hydrocortisone (SoluCortef ® , Pfizer, New York City, USA) one hour before operation; and another dose of 100 mg hydrocortisone was given perioperatively. After surgery, patients were transferred to intermediate care unit (IMCU) . A postoperative CT scan was performed in all patients around six hours after surgery to exclude major bleeding or serious complications. The next morning patients were transferred to the general ward and mobilised. They received 100 mg of hydrocortisone on the first and 50 mg on the second postoperative day. On the morning of the third operative day and/or before discharge, pituitary function was re-examined. If patients' cortisol levels were below 200 nmol/l in early morning blood samples, they received 30 mg of hydrocortisone (Hydrocortone ® , Merck, Darmstadt, Germany) per day until endocrinological follow-up as outpatients four weeks after surgery.
Surgery and intraoperative neuroimaging
All operations were performed in general anaesthesia. Patients were put in supine position on a foldable standard operation table with their head slightly reclined. The head was then fixed in a MRI-compatible head holder after adjusting the radio frequency coil around the patients head. The iMRI scanner used in all patients was a PoleStar™ N20 (0.15 Tesla, Medtronic Navigation, Louisville, CO, USA). Afterwards the intraoperative navigation system (Stealth Station, Medtronic Navigation, Louisville, CO, USA) was referenced with preoperative CT studies. The position of the patient's head in the scanner was tested by performing a 24 second sagittal e-steady scan (8 mm slices) and adjusted if necessary. Before surgery, a 7-minute, T1-weighted, gadolinium (20 ml Dotarem ® , Guerbet, Roissy CdG Cedex, France) enhanced, 4 mm slice, coronal iMRI scan was performed. These images were automatically loaded into the navigation system and merged with the preoperative imaging studies. All parts of surgical procedures were performed by using an operating microscope (Pentero ® , Carl Zeiss, Oberkochen, Germany). At the beginning of operations a self-retaining endonasal speculum was inserted in the nostril chosen for surgical approach. The mucosa was incised and partially removed, the posterior bony part of the septum was removed and the anterior wall of the sphenoid sinus was displayed. The anterior wall of the sphenoid sinus was then opened with punches, the intrasphenoidal mucosa and septum were removed and the inferior and anterior surface of the sella was displayed and opened with a chisel. The dura mater was opened in an x-shaped fashion and the adenoma removed by curettes, grasping forceps and suction devices. Tumour material was sent for frozen sections and neurohistopathological examination. After complete tumour removal according to the surgeon's impression, a 3.5-minute, T1-weighted, gadoliniumenhanced, 4 mm slice, coronal iMRI scan was performed for resection control in all patients. For better visualisation of possible tumour remnants, a glove-covered ball of bone wax was inserted into the resection cavity for hemostasis and improved interpretation of intraoperative images. The intraoperatively acquired images were automatically merged with the existing preoperative and intraoperative imaging studies. In cases of visible tumour remnant, the resection cavity was re-examined and tumour remnants removed if possible. Analysis of the intraoperative imaging studies were performed by the most experienced surgeon participating in the procedure. Another post-resectional, intraoperative 3.5-minute, T1-weighted, gadolinium-enhanced, 4 mm slice, coronal iMRI scan was performed in those cases. The anterior wall of the sella turcica was reconstructed by using the extracted posterior part of the bony nasal or intrasphenoidal septum. In cases of intraoperative CSF leakage, the sella was packed with abdominal fat and use of fibrin sealant. No nasal packing was used. All operations were performed by the senior author.
Follow-up and definition of remission
All patients were followed-up four weeks postoperatively as outpatients in the endocrinology clinic; hormone levels were analysed and deficiencies replaced if necessary. Three months after surgery, patients received a postoperative MRI study for resection control and patients were seen for neurosurgical follow up and examination.
Patients with non-functioning PA were considered in remission if complete tumour resection could be performed during surgery and neuroradiological follow-up with highfield MRI could not show any signs for tumour remnant of re-growth. Patients with growth-hormone producing PA were considered in remission if the following criteria were fulfilled: complete tumour resection was possible, symptoms of acromegaly diminished, postoperative high-field MRI showed no signs of tumour remnant or re-growth and postoperative GH level were less than 1.0 µg/l.
Statistical analysis and neuroimaging
The statistical analysis was performed using Microsoft Excel (Version 2003) and SPSS Statistic software (Version 16.0). All pre-and postoperative imaging studies were analysed independently and blinded to the clinical outcome using standardised software (picture archiving and commu-
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Swiss Med Wkly. 2012;142:w13699 nication system, PACS). Tumour volume was calculated based on the diameter method (tumour volume = 4/3 * Pi * ½x * ½y * ½z), where x, y and z are the maximum diameters in the three axis.
Results
Intraoperative imaging (table 2)
On average, 2.51± 0.99 intraoperative imaging studies were acquired per patient; the first at the beginning of the surgical procedure for mapping with the preoperative high-field MRI and a CT study, and another scan was performed before closure to confirm tumour removal and to check for tumour remnant. Based on these images, 44 patients (29.7%) received further tumour removal since tumour remnants were detected. In this case, at least one further imaging study was made to check for further tumour remnant. The other 98 patients (66.2%) showed no sign of tumour remnant (86 patients) unless visible tumour remnant was left in place (12 patients) due to predictably high risk of complications in case of further tumour removal. The rate of patients in remission during the overall followup in this study was 75.5% within the group of patients not undergoing further tumour removal and 59.1% in the group undergoing further tumour removal. There were an additional 26 patients (17.6% of study group) in remission during follow-up due to intraoperative imaging that lead to complete adenoma resection.
Neurodiological follow-up (table 2)
Patients were seen for clinical and neuroradiological follow-up (1.5 Tesla MRI) three months after surgery. There was another MRI performed one year postoperatively, and further imaging studies during overall followup in case of visible tumour remnant, tumour regrowth or newly developed symptoms. Overall mean follow-up during this study was 32 months (range 4-62 months). There were 106 patients considered tumour remnant-free, and 101 of them were considered to be in remission. The Three patients needed transsphenoidal revision surgery for CSF fistula with associated meningitis and one for CSF fistula alone. Two patients died during the study period for reasons considered unrelated to the surgical procedure (one for unknown reasons 11 months after surgery at an age of 87 years, one for pneumonia at an age of 59 years 2 months after surgery). 
Endocrinological outcome
102 (31-492) and 101 (29-209) and mean prolactin level in µg/l was 25.07 (0.50-109.50) preoperatively and 15.
Discussion
In this largest study to date we analysed the postoperative outcome, neurological symptoms and postoperative pituitary function in 148 patients undergoing iMRI-assisted transsphenoidal surgery for GH-producing-and NFPAs. The overall remission rate during a mean follow-up of 32 months (4-62) was 101 out of 148 patients (68.2%) applying the remission criteria of the latest international consensus conference regarding the GH-producing PAs and not detectable tumour remnant or re-growth in neuro-radiological follow-up with high-field MRI in patients with NFPA. These results are at least as good as previously published series reporting remission rates between 25 and 70% [5, 27, [34] [35] [36] [37] [38] [39] [40] [41] . Comparison remains difficult as most of the series included all kind of PAs but did not include giant adenomas, and remission criteria differed widely. Our results show that pituitary function was preserved in most of the patients as there were only 5 patients (3.4%) showing postoperative pituitary insufficiency and need for permanent medical treatment, which is in accordance with the literature showing rates ranging from 5.6% to 30.0% [42] . Mean hormone values showed no significant differences between pre-and postoperative endocrinological examinations in this study. Adenoma resections even led to complete recovery of pituitary function in 24 patients so that overall, 19 patients (12.8%) less remained dependent on permanent substitution therapy. Comparison with other published series is difficult as patient groups, type of included adenoma and other study parameters differ widely. Interestingly, remission rates were not related to postoperative need for further hormone substitution, which has already been shown in the literature [42] . Among the patients with preoperative pituitary insufficiency, 36 patients were in remission while 26 patients were not. There was no need for further hormone substitution in 14 out of these 36 patients (38.9%) and in 10 out of those 26 patients (38.5%). The surgical method used appeared safe as only a minor number of patients suffered complications. There were only four patients with need for re-operation because of CSF fistula and no patients with neurological deterioration due to surgery. The two deaths (one due to pneumonia) within the study population were considered unrelated to the surgical procedure. This all adds up to a remarkably low rate of complications compared to the literature; particularly considering that 15 patients with giant adenomas were included [24, [43] [44] [45] . Our results show that previous pituitary surgery elevates the risk of postoperative newly diagnosed pituitary insufficiency as all patients with new need for postoperative hor- Table 2 : Pre-, intra-and postoperative imaging.
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Swiss Med Wkly. 2012;142:w13699 D  0  0  1  CT, THT, GT  CT, THT  CT, THT, ADH  n   3  f  20  308  B  1  1  1  CT, THT, GT  CT, THT, GT  CT, THT, GT  n   4  m  58  132  A  1  0  0  CT, GT  CT  CT  n   5  m  48  50  A  0  0  0  GT  GT  GT  y   6  f There were some general limitations in this study that need to be considered. iMRI was thought to be helpful in surgery and to improve outcome so that it seemed unethical to perform surgery without iMRI in part of the study population. Pure endoscopic treatment of pituitary adenomas was not performed during the time of this study so there is no group of patients for comparison of the results within the same centre. This is especially a drawback as comparison to previously published series is complicated as not only the surgical method but also pre-and postoperative study protocols differ widely. Although the iMRI was useful and lead to improved remission rates and improved endocrinological-and neurological outcome there are some drawbacks in ultra-low field iMRI to consider as well. Even though studies have failed to show better results in surgical series using intraoperative high field MRI, image quality and resolution is -at least theoretically -better than in ultra-low field MRI [23, 41] . Costs for intraoperative imaging are still high due to installation, maintenance and time loss during surgery. Studies with larger patient numbers and cost/risk analysis should address the question of whether better clinical and endocrinological outcome can compensate for these increasing costs.
Conclusions
Data from this largest study to date analysing general postoperative outcome and pituitary function in patients undergoing ultra-low-field iMRI-assisted microsurgical treatment of PAs show that the presented method is a safe and highly effective treatment option. The results are at least as good as those reported in previously published serieseven in those with use of high-field iMRI or endoscopy. iMRI appeared to increase the rate of remission while keeping the complication rate low. Postoperative pituitary function was usually preserved and even improved in around 17% of the patients -possibly due to more exact and more extended iMRI-assisted tumour removal. This is not only a great achievement for each individual patient but also an important socioeconomic factor as hormone substitution therapy is expensive and health care systems worldwide face increasing budget deficits. Figures (large format) 
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